Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

This publication has 61 references indexed in Scilit:

• Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trials
  Seminars in Oncology, 2001
• Vascular Endothelial Growth Factor Can Substitute for Macrophage Colony-Stimulating Factor in the Support of Osteoclastic Bone Resorption
  The Journal of Experimental Medicine, 1999
• Heterocycle-Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure-Activity Relationships in J774 Macrophages
  Journal of Bone and Mineral Research, 1998
• Osteoclast Differentiation Factor (ODF) Induces Osteoclast-like Cell Formation in Human Peripheral Blood Mononuclear Cell Cultures
  Biochemical and Biophysical Research Communications, 1998
• Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double‐blind placebo‐controlled trial
  British Journal of Haematology, 1998
• A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
  British Journal of Haematology, 1998
• Soluble interleukin‐6 receptor as a prognostic factor in multiple myeloma
  British Journal of Haematology, 1996
• Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis
  Biochemical and Biophysical Research Communications, 1989
• Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro
  Journal of Bone and Mineral Research, 1989
• Long-Term Effects of Dichloromethylene Diphosphonate (Cl2 DP) on skeletal Lesions in Multiple Myeloma
  Metabolic Bone Disease and Related Research, 1982